Literature DB >> 11813188

Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.

Maren Tomaske1, Oliver Amon, Axel Bosk, Rupert Handgretinger, E Marion Schneider, Dietrich Niethammer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11813188     DOI： 10.1002/mpo.1294

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  10 in total

1.  Successful treatment of cerebral vasculitis in an HIV-positive patient with anti-CD25 treatment.

Authors:  C M G Nieuwhof; J Damoiseaux; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

2.  Lymphocyte-independent pathways underlie the pathogenesis of murine cytomegalovirus-associated secondary haemophagocytic lymphohistiocytosis.

Authors:  E Brisse; M Imbrechts; T Mitera; J Vandenhaute; N Berghmans; L Boon; C Wouters; R Snoeck; G Andrei; P Matthys
Journal:  Clin Exp Immunol       Date:  2018-01-18       Impact factor: 4.330

Review 3.  How I treat hemophagocytic lymphohistiocytosis.

Authors:  Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

4.  Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

Authors:  Rebecca A Marsh; Carl E Allen; Kenneth L McClain; Joanna L Weinstein; Julie Kanter; Jodi Skiles; Nadine D Lee; Shakila P Khan; Julia Lawrence; Jun Q Mo; Jack J Bleesing; Alexandra H Filipovich; Michael B Jordan
Journal:  Pediatr Blood Cancer       Date:  2012-04-22       Impact factor: 3.167

Review 5.  Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management.

Authors:  C Gholam; S Grigoriadou; K C Gilmour; H B Gaspar
Journal:  Clin Exp Immunol       Date:  2011-03       Impact factor: 4.330

Review 6.  Toxicity management for patients receiving novel T-cell engaging therapies.

Authors:  David M Barrett; David T Teachey; Stephan A Grupp
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

7.  Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.

Authors:  Rebecca L Olin; Kim E Nichols; Mojdeh Naghashpour; Mariusz Wasik; Brenda Shelly; Edward A Stadtmauer; Dan T Vogl
Journal:  Am J Hematol       Date:  2008-09       Impact factor: 10.047

Review 8.  Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Authors:  Shannon L Maude; David Barrett; David T Teachey; Stephan A Grupp
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360

Review 9.  Familial and acquired hemophagocytic lymphohistiocytosis.

Authors:  Gritta E Janka
Journal:  Eur J Pediatr       Date:  2006-12-07       Impact factor: 3.860

10.  Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis.

Authors:  Larisa Broglie; Lauren Pommert; Sridhar Rao; Monica Thakar; Rachel Phelan; David Margolis; Julie Talano
Journal:  Blood Adv       Date:  2017-08-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.